Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of Once Daily Oral ZPL-3893787 (30mg) Administered for 12 Weeks in Adults With Moderate to Severe Plaque Psoriasis

Trial Profile

Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of Once Daily Oral ZPL-3893787 (30mg) Administered for 12 Weeks in Adults With Moderate to Severe Plaque Psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs ZPL 3893787 (Primary)
  • Indications Plaque psoriasis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Ziarco
  • Most Recent Events

    • 23 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 24 Nov 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.
    • 24 Nov 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top